Microbiota as a Therapy

My Gut Microbiota, this new organ


The human baby encounters the microbial world at the moment of birth and naturally develops its own complex microbiota. This has happened in the very same way for millennia for the human species. Complex communities establish, develop and mature at all mucosal interfaces and on the skin. The distal parts of the intestine rapidly host a very dense and diverse community of 1 trillion bacteria per gram of intestinal content, composed for each individual of a fairly unique set of over 160 species, based on metagenomics sequencing, intimately associated with their host. Known as a new organ, the gut microbiota exerts essential functions contributing to digestive metabolism, protection against pathogens, stimulation of the immune system and intestinal epithelium. Thus, the balance of commensal bacteria in the gut microbial ecosystem is essential for the maintenance of health and well-being

My microbes and my cells, an intimate symbiosis


In evolution, microbes preceded more complex life-forms on earth and colonized essentially every possible ecological niche on the planet. Inner and outer compartments of protists, plants and animals became colonized by adapted microbial communities. Contemporary life-forms are essentially microbial entities known as holobionts.

In humans, the microbiota is in permanent interaction with the host at mucosal interfaces and the intestine is a privileged interface hosting the first pool of immune cells and the second pool of neural cells of the body. Intimate interactions provide the mutual benefits characteristic of a true symbiosis. For example, the immune system is permanently alert, sorting from sampled signals from microbes and cells at all mucosal interfaces including the intestine, and mounting appropriate responses in the presence of pathogens while keeping a tolerance towards microbial symbionts. A deregulated immune recognition of the commensal microbiota as part of ‘self’ leads to the pathological context of autoimmune and/or inflammatory bowel diseases.


Modern life shifted our Gut Microbiota leading to dysbiosis


Over only a few generations, humans have altered the trajectory of natural evolution of man-microbes symbiosis with fairly drastic changes in the environment and management of birth, with nutritional transition and with increased exposure to xenobiotic chemicals. This was associated with a rise in incidence of immune-mediated chronic diseases that continues, uncontrolled, predictions being that 1/3rd of the human population will be concerned by 2025. Not only do specificities of the microbiome show associations with diseases, but recurrent features, consistently associated on the host and microbiome sides, are highly evocative of an alteration of man-microbes symbiosis. Current clinical management or therapeutic measures designed to tackle symptoms will also most often induce or aggravate altered man-microbes symbiosis, leading to iatrogenic dysbiosis that can be considered as a clinical condition.

Fecal Microbiota Transfer-based drugs allow the treatment of dysbiosis


Understanding how we have altered the trajectory of natural evolution of man-microbes symbiosis will permit to define and validate strategies to prevent otherwise irreversible changes directly impacting health and well-being by promoting risk phenotypes. Furthermore, as we improve our understanding of man as a symbiosis, we can even envision innovative means to restore a functional health-prone symbiosis. In this context, Fecal Microbiota Transfer is a unique technology that allows to restore a beneficial microbiota but also acts at once on all features of host-microbes symbiosis. MaaT Pharma has established the first GMP platform in Europe supporting the development of FMT-based drugs.

Our Integrative Platform is Driven by 4 key pilars Enabling Drug Production and Development


Gut Print data science platform embeds a plethora of analysis modules and pipelines for multi-omics (metagenomics, genomics, metatranscriptomics, etc.), classical lab data and clinical data. Raw and analysed data are automatically integrated in our unified database. Gut Print is a cornerstone in the process of data-driven innovation of MaaT Pharma’s solutions by allowing to:

  • Find valuable insights in clinical and pre-clinical studies thanks to integrative data analyses
  • Thoroughly characterise human gut microbiome dysbiosis and correponding predictive signatures
  • Describe FMT modes of action in distinct clinical contexts
  • Bring standardisation solutions for MaaT microbiotherapies
  • Describe gut microbiome keystone species and strains, antibiotics resistance genes and metabolic functions


Partnering with MaaT Pharma to accelerate the access of our drugs to Patients

Right from the start, we have been working closely with researchers, academics, hospitals and private companies to resolve strategic medical and scientific questions. As we have grown and developed proprietary platforms and technologies, we’re expanding our network and are looking into entering additional partnerships using MaaT Pharma’s proprietary technology.

Feel free to reach out to us if you work in the field of treating iatrogenic modification of the Gut Microbiota dysbiosis (antibiotics, chemotherapies, stem cell transplantation conditioning) in hematologic malignancies, or other life-threatening situations as well as immuno-oncology.

For more information please contact us at: collaborations@maat-pharma.com

+33 (0)4 28 29 14 00